Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Doxorubicin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    596 result(s) found for: Doxorubicin. Displaying page 1 of 30.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001443-63 Sponsor Protocol Number: 01062 Start Date*: 2006-07-10
    Sponsor Name:European Lung Cancer Working Party
    Full Title: A phase II study assessing the activity of valproate acid plus doxorubicin in refractory or recurrent malignant mesothelioma.
    Medical condition: This is a prospective phase II study investigating well-known antimetabolite (doxorubicin) and antiepileptic (valproate) drugs, in combination, for the treatment of refractory or recurrent malignan...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004927-11 Sponsor Protocol Number: INNO-206-P2-STS-01 Start Date*: 2012-03-02
    Sponsor Name:CytRx Corporation
    Full Title: A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects with Metastatic, Locally A...
    Medical condition: Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003324-36 Sponsor Protocol Number: NT14035-3/2013 Start Date*: 2013-11-07
    Sponsor Name:Charles University in Prague, Faculty of Medicine in Hradec Králové
    Full Title: Kinetically guided removal of plazma pegylated liposomal doxorubicin to enhance the benefit of cytostatic therapy of patients with ovarian cancer.
    Medical condition: Primary aim: enhanced therapeutic benefit of liposomal doxorubicin - a drug indicated for ovarian cancer resistant to chemotherapy with the first line drugs. This approach can be considered a model...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001244-56 Sponsor Protocol Number: LiCTOP-C-001 Start Date*: 2013-07-23
    Sponsor Name:Department of Pharmacy, Uppsala University
    Full Title: An open, multicenter, single dose, parallel study, evaluating the pharmacokinetics of doxorubicin and its active metabolite (doxorubicinol) after a hepatic intra-arterial injection of either a lipi...
    Medical condition: Intermediate hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000163-25 Sponsor Protocol Number: HE2006 Start Date*: 2005-08-04
    Sponsor Name:Research and Enterprise, University of Birmingham
    Full Title: Proteomics and Pharmacokinetics of Adriamycin Following Different Techniques for Chemoembolisation of Hepatocellular Carcinoma (PPATCH) Trial
    Medical condition: Hepatocellular cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004060-40 Sponsor Protocol Number: AGO15 Start Date*: 2008-03-13
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer
    Medical condition: primary advanced or recurrent/metastatic endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000547-14 Sponsor Protocol Number: BGOG-cx3 Start Date*: 2017-08-30
    Sponsor Name:BGOG-UZLeuven
    Full Title: BGOG-cx3: Prospective randomized Phase II trial comparing doxorubicin alone versus doxorubicin and atezolizumab in recurrent cervical cancer
    Medical condition: recurrent cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000366-36 Sponsor Protocol Number: TLK286.3025 Start Date*: 2006-06-07
    Sponsor Name:Telik, Inc.
    Full Title: Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory ...
    Medical condition: platinum refractory or resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033160 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001770-40 Sponsor Protocol Number: 11546 Start Date*: 2005-06-03
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma.
    Medical condition: advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10049010 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002625-35 Sponsor Protocol Number: CALGB80802 Start Date*: 2013-09-23
    Sponsor Name:All Ireland Co-operative Oncology Research Group (ICORG)
    Full Title: Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)
    Medical condition: Advanced or Metastatic Hepatocellular Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003145-17 Sponsor Protocol Number: TH-CR-406/SARC021 Start Date*: 2012-02-28
    Sponsor Name:Threshold Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue S...
    Medical condition: Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) HU (Completed) PL (Prematurely Ended) BE (Completed) IT (Completed) AT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000134-30 Sponsor Protocol Number: I5B-MC-JGDJ Start Date*: 2015-09-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
    Medical condition: Advanced or Metastatic Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) SE (Ongoing) FI (Completed) BE (Completed) NL (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003091-77 Sponsor Protocol Number: B9991009 Start Date*: 2016-03-16
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin Alone to In Patien...
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) AT (Completed) ES (Completed) GR (Completed) IE (Completed) NL (Completed) FR (Completed) PL (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-002399-40 Sponsor Protocol Number: Start Date*: 2005-05-11
    Sponsor Name:Rigshospitalet
    Full Title: Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.
    Medical condition: Recurrent ovarian cancer Cytologic / histologic diagnosis of stage IC-IV ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001783-75 Sponsor Protocol Number: SATCG-4 Start Date*: 2008-03-31
    Sponsor Name:Department of Oncology, Lund University Hospital
    Full Title: Phase 2 trial with Avastin and Doxorubicin postoperatively for patients with anaplastic thyroid carcinoma
    Medical condition: Patients that suffer from anaplastic thyroid cancer and have completed our "standard" initial therapy with radiotherapy and chemotherapy, and has been macroscopical radically resected after complet...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000915-80 Sponsor Protocol Number: NB 2006 05 Start Date*: 2005-09-06
    Sponsor Name:University of Birmingham
    Full Title: A phase II study of Topotecan-Vincristine-Doxorubicin (TVD) in children with stage 4 neuroblastoma failing to respond to COJEC
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029260 Neuroblastoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004088-77 Sponsor Protocol Number: BA2006/03/03 Start Date*: 2007-12-03
    Sponsor Name:BioAlliance Pharma
    Full Title: Doxorubicin-Transdrug® in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.
    Medical condition: Advanced hepatocarcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005862-36 Sponsor Protocol Number: mammatherm Start Date*: 2007-07-16
    Sponsor Name:Klinikum der Universität München Innenstadt, I. Frauenklinik
    Full Title: Prospectively Randomized Phase I/II Trial of Liposomal-encapsulated Doxorubicin and Cisplatin +/- Locoregional Hyperthermia in patients with Metastatic Breast Cancer
    Medical condition: This is an open-label, multicenter, randomized controlled, Phase I/II study comparing the time to progressive disease after randomisation in patients treated with 6 cycles of liposomal-encapsulated...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003648-55 Sponsor Protocol Number: EZH-301 Start Date*: 2020-08-17
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
    Medical condition: Phase 1b: Have histologically confirmed Soft tissue sarcoma (STS). Phase 3: Morphology and immunophenotypic panel consistent with epithelioid sarcoma (eg, CD34, epithelial membrane antigen [EMA], ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004822-19 Sponsor Protocol Number: ICORG 05-11/NSABP B-38 Start Date*: 2006-02-15
    Sponsor Name:ICORG the all Ireland Co-operative Oncology Research Group
    Full Title: A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphami...
    Medical condition: Early stage node positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:40:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA